Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

doi: 10.1016/j.jaip.2021.02.054

Figure Lengend Snippet: Approaches to COVID-19 vaccine evaluated included universal vaccination vs a risk-stratified approach, with primary outcomes of total hospitalizations and fatalities evaluated from a health care perspective.

Article Snippet: The Pfizer-BioNTech COVID-19 vaccine EUA was based on safety data of 37,586 participants in an ongoing multinational randomized placebo controlled trial including the United States, who were followed for a median of 2 months after the second dose of vaccine administration.

Techniques:

Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

doi: 10.1016/j.jaip.2021.02.054

Figure Lengend Snippet: One-way sensitivity analysis of anaphylaxis risk. When risk of vaccine anaphylaxis exceeds 0.8%, risk stratification was the most cost-effective strategy (WTP = 10,000,000 per death prevented). Typical rates of vaccine anaphylaxis are estimated at 1.3 per million, with COVID-19 anaphylaxis rates estimated at 11.1 per million. , WTP , Willingness to pay.

Article Snippet: The Pfizer-BioNTech COVID-19 vaccine EUA was based on safety data of 37,586 participants in an ongoing multinational randomized placebo controlled trial including the United States, who were followed for a median of 2 months after the second dose of vaccine administration.

Techniques:

Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

doi: 10.1016/j.jaip.2021.02.054

Figure Lengend Snippet: Two-way sensitivity analysis of anaphylaxis risk and COVID-19 risk. As risk of COVID-19 increased, cost-effectiveness of a risk-stratified approach required vaccine deferral at higher anaphylaxis risk thresholds.

Article Snippet: The Pfizer-BioNTech COVID-19 vaccine EUA was based on safety data of 37,586 participants in an ongoing multinational randomized placebo controlled trial including the United States, who were followed for a median of 2 months after the second dose of vaccine administration.

Techniques:

Journal: Molecular Immunology

Article Title: Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2

doi: 10.1016/j.molimm.2023.03.009

Figure Lengend Snippet: Proposed kinetics of immune responses and their relationship with the severity of the SARS-CoV-2 infection in non-severe (mild/ moderate) vs. severe patients (survivors and nonsurvivors). Graphical representation of various immune responses kinetics and disease pathology in different categories of COVID-19 patients based on the current understanding. Panels A, B, and C represent the kinetics of immune responses and disease pathology in mild/ moderate, severe survivor and severe non-survivor patients, respectively. The x-axis in each panel represents the progression of the disease symptoms/ pathology with a tentative timeline in days . The left y-axis represents the severity of the disease for each patient category. The right y-axis represents the relative immune responses (arbitrary representation) of IFNs and proinflammatory cytokines (Red line), SARS-CoV-2 specific antibody (black line), and 3 lymphocytes count (blue line). The scales on the y-axis are relative to the maximum amplitude in non-survivors and the comparison among the panels is qualitative. The kinetics of antibody production in severe and non-severe cases are described by and . The kinetics of lymphocytes number in nonsevere and severe is described by and . The IFNs and proinflammatory cytokine production kinetics are compiled from SARS-CoV-2, SARS-CoV and MERS-CoV infection (Zhou et al., 2020c, Oberfeld et al., 2020). Data reported in multiple articles are combined to recapitulate the kinetics of disease progression and immune response and may not accurately represent all patients . tables.

Article Snippet: On December 2022, Pfizer-BioNTech released COVID-19 vaccination for children aged 6 months - 4 years, thus covering almost the entire population range.

Techniques: Infection